Taho Pharmaceuticals Ltd.

TPEX:6467 Stock Report

Market Cap: NT$2.7b

Taho Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Taho Pharmaceuticals's earnings have been declining at an average annual rate of -59.7%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been declining at an average rate of 123.9% per year.

Key information

-59.7%

Earnings growth rate

-43.9%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate-123.9%
Return on equity-61.1%
Net Margin16,656.9%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Taho Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:6467 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24-1-14916133
31 Mar 240-13515120
31 Dec 231-12115106
31 Dec 226-661755
31 Dec 217-111664
30 Jun 189-1012770
31 Mar 1811-1193171
31 Dec 1712-1373571
30 Sep 1719-1314265
30 Jun 1725-1244860
31 Mar 1730-1175362
31 Dec 1636-1095864
30 Sep 1636-956470
30 Jun 1637-816976
31 Mar 1636-786975
31 Dec 1535-746974
30 Sep 1533-996671
30 Jun 1531-1236367
31 Mar 1526-1255867
31 Dec 1420-1265466
30 Sep 1417-1135359
30 Jun 1414-1005253
31 Mar 1414-935544

Quality Earnings: 6467 is currently unprofitable.

Growing Profit Margin: 6467 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 6467's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare 6467's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6467 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.9%).


Return on Equity

High ROE: 6467 has a negative Return on Equity (-61.08%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/20 10:45
End of Day Share Price 2025/01/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Taho Pharmaceuticals Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution